Summary
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
History
Guardant Health was founded in 2012 by AmirAli Talasaz and Helmy Eltoukhy. Guardant Health launched its first commercial sequencing test, Guardant360, in 2014. In 2016, Guardant Health launched GuardantOMNI, a comprehensive liquid biopsy test with best-in-class accuracy. In 2018, the company launched Guardant Reimbursement Solutions, which works to make sure patients get reimbursed for their tests.
Mission
Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics.
Vision
We strive to make precision oncology a reality for cancer patients globally, through technology-driven testing, powerful data, and our best-in-class clinical insights.
Key Team
Mr. John G. Saia (Chief Legal Officer)
Dr. Craig Eagle M.D. (Chief Medical Officer)
Mr. Christopher Freeman (Chief Commercial Officer of Oncology Bus.)
Mr. Andy Ament (Sr. VP of Operations)
Darya Chudova (Sr. VP of Technology)
Mr. Kumud Kalia (Chief Information Officer)
Ms. Jennifer Higgins (VP of Public Affairs)
Recognition and Awards
Guardant Health has been named a “Top 10 Innovative Company in Healthcare” by Fast Company in 2018 and a “Top 10 Company to Watch” by Goldman Sachs in 2019.
References
United States 
